Ir para o conteúdo principal

In8bio Inc (NASDAQ: INAB) — Perfil da empresa, notícias e dados financeiros

Logo de In8bio Inc
INAB In8bio Inc
In8bio Inc primary media
Perfil da empresa

In8bio Inc

In8bio (NASDAQ:INAB) is a dynamic company focused on developing innovative cancer therapies using gamma-delta T cells, aimed at treating a variety of cancers. Its operations revolve around leveraging cutting-edge science to engineer treatments that are both effective and safe for patients. Among its projects are clinical trials aimed at proving the efficacy and safety of its groundbreaking therapies. The company's primary objectives include advancing its pipeline of gamma-delta T cell therapies through clinical development, with the ultimate goal of bringing new cancer treatments to market that can improve patient outcomes and quality of life. In8bio is dedicated to pushing the boundaries of cancer treatment, aiming to make a significant impact in the fight against this challenging disease.

Resumo

Public USParticipação acionária
2016Ano de fundação
38Funcionários
New York, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
New York City, US

Produtos e/ou serviços de In8bio Inc

  • Gamma-delta T cells therapies for solid and liquid tumors, emphasizing innovative cancer treatments.
  • DeltEx platform to enhance gamma-delta T cell proliferation and persistence for improved efficacy.
  • Checkpoint inhibitors designed to bypass cancer defense mechanisms, ensuring targeted treatment.
  • Allogeneic gamma-delta T cell therapies, offering scalable and accessible cancer treatment options.
  • INB-200, a novel treatment for glioblastoma, focusing on a hard-to-treat brain cancer.
  • INB-100, a leukemia treatment designed for patients post-allogeneic transplant, aiming at preventing relapse.

equipe executiva do In8bio Inc

  • Tai-Wei HoCo-Founder, CEO & Director
  • Kate RochlinPresident & COO
  • Patrick McCallCFO & Secretary
  • Lawrence S. LambExecutive VP, Co-Founder & Chief Scientific Officer
  • Oxana PolyakovaSenior Vice President of Research & Development

Principais indicadores financeiros

Resultados divulgados pela In8bio Inc, em USD.

Cap. de mercado
10,1 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-1.6
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da In8bio Inc
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-19,9 mi-19,4 mi
0-30,4 mi-30,4 mi
0-30,3 mi-30 mi
0-28,5 mi-27,4 mi